Remoxipride

Summary

Remoxipride (CHEMBL22242) is an approved small molecule (ATC N05AL04); indicated across 1 condition including psychotic disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05AL04
• Indications: 1 condition
• Chemistry: 371.27 Da · C16H23BrN2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL22242
Name	Remoxipride
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	54477
ATC	N05AL04
Molecular formula	C16H23BrN2O3
Molecular weight	371.27
InChIKey	GUJRSXAPGDDABA-NSHDSACASA-N

SMILES: CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2OC)Br)OC

IUPAC name: 3-bromo-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxybenzamide

Also known as: A 33547, A-33547, A-33547.HCL.H20, FLA 731, FLA 731 FREE BASE, FLA-731 FREE BASE, FLA-731(-), Remoxiprida, Remoxipride, SID11112836, SID11113786, SID26751966

Parent form; salt/anhydrous children: CHEMBL1899328, CHEMBL3989556

Patent coverage: 797 distinct patent families (3,057 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 18 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, Menin/Histone-lysine N-methyltransferase MLL, Dopamine receptor, 5-hydroxytryptamine receptor 1A, D(2) dopamine receptor, D(4) dopamine receptor, Alpha-1A adrenergic receptor, D(3) dopamine receptor.

Bioactivity

ChEMBL activities: 23 potent at pChembl ≥ 5 of 27 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DRD2	8.92	IC50	1.2	nM	CHEMBL_ACT_3550732
SIGMAR1	7.26	Ki	55	nM	CHEMBL_ACT_51734
CYP2D6	6.7	Potency	199.5	nM	CHEMBL_ACT_4986094
CYP2D6	6.7	AC50	199.5	nM	CHEMBL_ACT_5988020
DRD2	6.06	IC50	880	nM	CHEMBL_ACT_303812
P52702	6.06	Ki	873	nM	CHEMBL_ACT_48192
HTR2B	5.99	AC50	1032	nM	CHEMBL_ACT_25164260
DRD2	5.93	AC50	1162	nM	CHEMBL_ACT_25140920
P61169	5.85	IC50	1400	nM	CHEMBL_ACT_51735
P61169	5.8	IC50	1570	nM	CHEMBL_ACT_1172355
P18901	5.8	IC50	1570	nM	CHEMBL_ACT_523761
P61169	5.8	IC50	1570	nM	CHEMBL_ACT_70963
HIF1A	5.7	Potency	1995	nM	CHEMBL_ACT_4128013
HIF1A	5.7	Potency	1995	nM	CHEMBL_ACT_4520622
HTR2B	5.51	AC50	3063	nM	CHEMBL_ACT_25228080
DRD4	5.41	IC50	3872	nM	CHEMBL_ACT_303813
DRD4	5.41	Ki	3872	nM	CHEMBL_ACT_48194
HTR1A	5.4	Kd	3981	nM	CHEMBL_ACT_2930090
P52703	5.34	Ki	4603	nM	CHEMBL_ACT_48193
ADRA2C	5.26	AC50	5500	nM	CHEMBL_ACT_25148470
DRD3	5.21	AC50	6148	nM	CHEMBL_ACT_25194106
KCNH2	5.14	AC50	7204	nM	CHEMBL_ACT_25118706
ADRA2A	5.11	AC50	7743	nM	CHEMBL_ACT_25156090

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
psychotic disorder	4	MONDO:0005485	EFO:0005407

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).